

# IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS    BT2024197    DECEMBER 5, 2024

---

## **IHCP announces additional COVID-19 coverage changes due to American Rescue Plan expiration**

Effective immediately, retroactive for dates of service (DOS) on or after **Oct. 1, 2024**, the Indiana Health Coverage Programs (IHCP) announces coronavirus disease 2019 (COVID-19) vaccine, testing and treatment coverage changes. Changes to coverage are a result of the expiration of the *American Rescue Plan Act of 2021 (ARP)* requirements on Sept. 30, 2024. For further information regarding the end of the COVID-19 public health emergency (PHE), the U.S. Department of Health and Human Services (HHS) has published a [fact sheet](#).



### **COVID-19 vaccines**

The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) have added COVID-19 vaccination to the Child and Adolescent and Adult Immunization Schedules. As established in *IHCP Bulletin* [BT201960](#), COVID-19 vaccines will continue to be available without cost sharing for eligible IHCP members through the Vaccines for Children (VFC) program.

COVID-19 vaccine administration reimbursement will remain at the adjusted Medicare rate; however, reimbursement for commercially available COVID-19 vaccines will follow reimbursement methodology consistent with all other vaccines that process through the medical benefit.

---

***Revised reimbursement does not apply to current federally qualified health center (FQHC) or rural health clinic (RHC) methodology and guidance.***

---

Effective retroactively for DOS on or after Oct. 1, 2024, the COVID-19 vaccine procedure codes in [Table 1](#) will no longer be covered for members in limited-benefit categories, including Emergency Services Only and the Family Planning Eligibility Program.

Stand-alone COVID-19 vaccination counseling was added as part of the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit per *IHCP Bulletins* [BT202247](#) and [BT202278](#). Changes to that benefit were announced in *IHCP Bulletin* [BT2024135](#).

### **COVID-19 testing**

As announced in *IHCP Bulletin* [BT2024135](#), effective Oct. 1, 2024, at-home COVID-19 tests will no longer be covered through the IHCP pharmacy benefit. Coverage of COVID-19 testing will continue to be available for eligible IHCP members through the medical benefit, except for the limited-benefit programs as listed in Table 1.

### COVID-19 treatments

Cost-share removal requirements related to COVID-19 treatments will sunset. This includes treatments for acute infection, post-COVID-19 conditions and the treatment of a condition that could seriously complicate COVID-19 infection for the period in which the member is experiencing COVID-19 infection.

Additionally, the IHCP will discontinue reimbursement of COVID-19 treatments that have not obtained U.S. Food and Drug Administration (FDA) approval.

Effective retroactively for DOS on or after Oct. 1, 2024, the COVID-19 treatments listed in Table 1 will no longer be a covered services for members in limited-benefit programs, including Emergency Services Only.

### For more information

Questions about claim submission for members in the Healthy Indiana Plan (HIP), Hoosier Care Connect, Hoosier Healthwise or Indiana PathWays for Aging (PathWays) should be directed to the managed care entity (MCE) with which the member is enrolled.

Questions about fee-for-service (FFS) member medical benefits should be directed to Gainwell Technologies Customer Assistance at 800-457-4584 or your [Provider Relations consultant](#).

*Table 1 – COVID-19 procedure codes no longer covered for limited-benefit programs, effective for DOS on or after Oct. 1, 2024*

Procedure code	Description
86328	Test for detection of severe acute respiratory syndrome coronavirus 2 (COVID-19) antibody, qualitative or semiquantitative
86408	Screening test for detection of severe acute respiratory syndrome coronavirus 2 (COVID-19) neutralizing antibody
86409	Measurement of neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (COVID-19)
86769	Measure of severe acute respiratory syndrome coronavirus 2 (COVID-19) antibody
87426	Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus
87428	Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza
87635	Amplified DNA or RNA probe detection of severe acute respiratory syndrome coronavirus 2 (COVID-19) antigen
87636	Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (COVID-19) and influenza virus types A and B
87637	Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (COVID-19), influenza virus types A and B, and respiratory syncytial virus
87811	Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (COVID-19)
87913	Genotype analysis of severe acute respiratory syndrome coronavirus 2 (COVID-19) by nucleic acid for identification of mutations in targeted regions
90480	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, single dose
91304	Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use
91318	Severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 ml dosage, tris-sucrose formulation, for intramuscular use

*Table 1 – COVID-19 procedure codes no longer covered for limited-benefit programs, effective for DOS on or after Oct. 1, 2024 (Continued)*

Procedure code	Description
91319	Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 ml dosage, tris-sucrose formulation, for intramuscular use
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 ml dosage, tris-sucrose formulation, for intramuscular use
91321	Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 ml dosage, for intramuscular use
91322	Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 ml dosage, for intramuscular use
0240U	Respiratory infectious agent detection by RNA for severe acute respiratory syndrome coronavirus 2 (COVID-19), influenza A, and influenza B) in upper respiratory specimen, each reported as detected or not detected
0241U	Respiratory infectious agent detection by RNA for severe acute respiratory syndrome coronavirus 2 (COVID 19), influenza A, influenza B, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected
Q0240	Injection, casirivimab and imdevimab, 600 mg
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg
U0001	CDC 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel
U0002	2019-ncov coronavirus, SARS-COV-2/2019-ncov (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC

**QUESTIONS?**

If you have questions about this publication, please contact Customer Assistance at 800-457-4584.

**COPIES OF THIS PUBLICATION**

If you need additional copies of this publication, please download them from the [IHCP Bulletins](#) page of the IHCP provider website at [in.gov/medicaid/providers](http://in.gov/medicaid/providers).

**SIGN UP FOR IHCP EMAIL NOTIFICATIONS**

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the [IHCP provider website](#) at [in.gov/medicaid/providers](http://in.gov/medicaid/providers).

